Liminatus Pharma, Inc. Class A Common Stock

LIMNNASDAQHealthcare● Active

$0.14

$-0.00(-0.84%)

Market Cap$3783510

P/E Ratio—

52W High$33.66

52W Low$0.132

Avg Volume10.1M

Open$0.14

Beta0.70

Earnings Financials Revenue

Liminatus Pharma, Inc. Class A Common Stock (LIMN) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

LIMN · earnings · updated Jun 9, 2026

Latest Earnings

Q2 FY2026Report Date: May 15, 2026

EPS Actual

-$0.03

Revenue

—

Fiscal Period

Q2 FY2026

FY ends December

Report Date

May 15, 2026

After Market Close

LIMN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$1.00

Rev. $1.80B

Days Away84

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$1.00

Rev. Est.$1.80B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
— Q2 FY2026	May 15, 2026	—	-$0.03	—	—	—	—
— Q1 FY2026	Mar 31, 2026	—	-$0.03	—	—	—	—
— Q4 FY2025	Nov 13, 2025	—	-$0.07	—	—	—	—
— Q4 FY2025	Oct 3, 2025	—	-$0.05	—	—	—	—

Q2 FY2026

May 15, 2026

EPS Actual

-$0.03

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2026

Mar 31, 2026

EPS Actual

-$0.03

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2025

Nov 13, 2025

EPS Actual

-$0.07

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2025

Oct 3, 2025

EPS Actual

-$0.05

EPS Est.

—

EPS Surpr.

—

Revenue

—

No analyst estimates available for LIMN.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q2 FY2026	May 15, 2026	—	$0.18	$0.18	-2.17%
— Q1 FY2026	Mar 31, 2026	—	$0.18	$0.17	-2.88%
— Q4 FY2025	Nov 13, 2025	—	$1.17	$1.07	-8.55%
— Q4 FY2025	Oct 3, 2025	—	$1.96	$1.73	-11.73%

Q2 FY2026-2.17%

Report Date

May 15, 2026

EPS Beat/Miss

—

Price Before

$0.18

Price After

$0.18

Q1 FY2026-2.88%

Report Date

Mar 31, 2026

EPS Beat/Miss

—

Price Before

$0.18

Price After

$0.17

Q4 FY2025-8.55%

Report Date

Nov 13, 2025

EPS Beat/Miss

—

Price Before

$1.17

Price After

$1.07

Q4 FY2025-11.73%

Report Date

Oct 3, 2025

EPS Beat/Miss

—

Price Before

$1.96

Price After

$1.73

Beat Rate0 / 4 quarters

Largest Move-11.73% (Q4 FY2025)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Liminatus Pharma, Inc. Class A Common Stock (LIMN) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.03 (in line with the analyst consensus of —). The next LIMN earnings date is expected around September 1, 2026.

Each quarter, investors track LIMN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LIMN revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

LIMN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

LIMN earnings · 4 questions

Liminatus Pharma, Inc. Class A Common Stock's next earnings report is expected around September 1, 2026. LIMN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LIMN historically reports after market close (AMC).

LIMN earnings datewhen is LIMN earningsLIMN next earnings datewhen does LIMN report earningsLIMN earnings calendar

▸ Source: FMP · Liminatus Pharma, Inc. Class A Common Stock SEC filings · US GAAP · Liminatus Pharma, Inc. Class A Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026